| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5697713 | Clinical Oncology | 2017 | 7 Pages |
Abstract
There are significant differences in PET and EUS measurement of LoD. This could affect clinical decision making and radiotherapy treatment planning. Clinically significant differences between EUS and PET LoD could lead to a risk of geographical miss in up to 38.1% of cases if the PET/CT measurement alone had been used for radiotherapy planning. These results highlight the continued benefit of EUS in the oesophageal cancer staging and treatment pathway.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
K.G. Foley, C. Morgan, S.A. Roberts, T. Crosby,